Integra LifeSciences (IART) Expected to Announce Earnings on Tuesday

Integra LifeSciences (NASDAQ:IART) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Integra LifeSciences to post earnings of $0.86 per share and revenue of $445.15 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Integra LifeSciences Stock Performance

IART opened at $24.18 on Tuesday. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.87 billion, a PE ratio of -268.64, a P/E/G ratio of 0.87 and a beta of 1.17. The firm has a 50 day moving average of $23.86 and a two-hundred day moving average of $21.82.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IART. Citigroup lifted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average target price of $23.00.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is owned by corporate insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.